News - Marketing authorisation medicines for human use

19 news items Marketing authorisation medicines for human use

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period
Sort by:
Subscribe to news from this organisation
  1. MEB advises to put AstraZeneca vaccination temporarily on hold

    The Medicines Evaluation Board (MEB) has advised Minister De Jonge of Health, Welfare and Sport (VWS) to consider to put the ...

    News item | 14-03-2021 | 23:00

  2. DCP time slot application available again

    The DCP time slot application is available again. Maintenance work has been completed.

    News item | 27-01-2021 | 10:00

  3. Implementation of the Medical Device Regulation postponed until 26 May 2021

    Due to the coronavirus crisis the European Commission has postponed the implementation of the new Medical Device Regulation (MDR, ...

    News item | 08-05-2020 | 17:00

  4. MEB Portal shut down permanently

    For safety reasons, the MEB portal was provisionally taken offline in January this year. Unfortunately, the MEB has had to take ...

    News item | 20-04-2020 | 12:00

  5. Request to take over the Fucidin marketing authorisation

    The company Leo Pharma B.V. has informed the Medicines Evaluation Board (MEB) that the production of the antibiotic Fucidin ...

    News item | 31-03-2020 | 17:00

  6. Request to take over the pyridoxine hydrochloride marketing authorisation

    The company Pharmachemie B.V. has requested the Medicines Evaluation Board (MEB) to withdraw marketing authorisation for ...

    News item | 30-03-2020 | 17:00

  7. Changes to product information policy

    The Medicines Evaluation Board (MEB) recently revised a number of policy documents for pharmaceutical companies relating to the ...

    News item | 23-03-2020 | 12:00

  8. Amended policy on DHPCs

    The Medicines Evaluation Board (MEB) has amended its policy on Direct Healthcare Professional Communications (DHPCs). This ...

    News item | 21-02-2020 | 12:00

  9. MEB confirms current legal status of supply ibuprofen 200 mg

    The Medicines Evaluation Board (MEB) has evaluated whether the recent European review of the adverse events on heart and blood ...

    News item | 03-08-2015 | 00:00

Go to